<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684307</url>
  </required_header>
  <id_info>
    <org_study_id>D1250C00008</org_study_id>
    <nct_id>NCT00684307</nct_id>
  </id_info>
  <brief_title>Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation</brief_title>
  <official_title>A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, Given as an Extended-release Formulation, in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to provide dose-guiding information by assessing the safety
      and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of
      AZD0837 compared with well-controlled, dose-adjusted Vitamin-K antagonists (VKA) (aiming for
      an international normalized ratio (INR) 2.0 to 3.0) in patients with non-valvular atrial
      fibrillation (AF) with one or more additional risk factors for stroke.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>36 weeks according to protocol. For patients who discontinued treatment the time frame was &lt;36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)</time_frame>
    <description>Number of patients with a bleeding event while on study drug. Patients with multiple events are counted once</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine</measure>
    <time_frame>12 weeks according to protocol.(baseline to week 12 visit)</time_frame>
    <description>Change in Creatinine values from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine Aminotransferase (ALAT)</measure>
    <time_frame>36 weeks according to protocol. For patients who discontinued treatment the time frame was &lt;36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)</time_frame>
    <description>Number of patients while on study drug with ALAT&gt;=3 times upper limit of normal.l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>36 weeks according to protocol. For patients who discontinued treatment the time frame was &lt;36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)</time_frame>
    <description>Number of patients while on study drug with Bilirubin&gt;=2 times upper limit of normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>D-Dimer</measure>
    <time_frame>14 weeks according to protocol.(enrolment to week 12 visit)</time_frame>
    <description>Change in D-Dimer values from enrolment to week 12 visit for VKA naïve patients while on study drug (week 12 visit-enrolment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated Partial Thromboplastin Time (APTT)</measure>
    <time_frame>12 weeks according to protocol.(baseline to week 12 visit)</time_frame>
    <description>Change in Activated partial thromboplastin time (APTT) from baseline to week 12 visit for VKA naïve patients while on study drug (week 12 visit-baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ecarin Clotting Time (ECT)</measure>
    <time_frame>12 weeks according to protocol.(baseline to week 12 visit)</time_frame>
    <description>Change in Ecarin clotting time (ECT) from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of AZD0837 (Prodrug)</measure>
    <time_frame>12 weeks after baseline according to protocol</time_frame>
    <description>Assessment made on the week 12 visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of AR-H067637XX (Active Metabolite)</measure>
    <time_frame>12 weeks after baseline according to protocol</time_frame>
    <description>Assessment made on the week 12 visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TT</measure>
    <time_frame>36 weeks according to protocol</time_frame>
    <description>Oral clearance of AR-H067637XX in subgroup of patients with genotype TT for gene polymorphism ABCB1 C3435T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TC</measure>
    <time_frame>36 weeks according to protocol</time_frame>
    <description>Oral clearance of AR-H067637XX in subgroup of patients with genotype TC for gene polymorphism ABCB1 C3435T</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype CC</measure>
    <time_frame>36 weeks according to protocol</time_frame>
    <description>Oral clearance of AR-H067637XX in subgroup of patients with genotype CC for gene polymorphism ABCB1 C3435T</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1084</enrollment>
  <condition>Nonvalvular Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0837 450 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0837 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0837 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD0837 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin-K antagonist at INR 2-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0837</intervention_name>
    <description>ER tablet, PO, once daily for a period of 3-9 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin-K antagonist at INR 2-3</intervention_name>
    <description>Tablet, PO for a period of 3-9 months.</description>
    <arm_group_label>5</arm_group_label>
    <other_name>Warfarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0837</intervention_name>
    <description>ER tablet, PO, twice daily for a period of 3-9 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nonvalvular AF (NVAF) verified by at least two ECGs in the last year separated by at
             least one week.

          -  Previous cerebral ischemic attack (stroke or TIA, &gt;30 days prior to randomization)

          -  Previous systemic embolism.

          -  Symptomatic congestive heart failure (CHF)

          -  Impaired left ventricular systolic function

          -  Diabetes mellitus

          -  Hypertension requiring anti-hypertensive treatment.

        Exclusion Criteria:

          -  AF secondary to reversible disorders, eg hyperthyroidism, drugs and pulmonary embolism

          -  Known contraindication to VKA treatment

          -  Presence of a valvular heart disease, mechanical heart valves, active endocarditis,
             left ventricular aneurysm or thrombus, atrial myxoma or any condition other than AF
             requiring chronic anticoagulation treatment

          -  Conditions associated with increased risk of major bleeding for example: history of
             intracranial bleeding, history of bleeding gastrointestinal disorder or major surgical
             procedure or trauma two weeks prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Y Lip, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Department of Medicine, City Hospital, Birmingham, B18 7QH, England, UK</affiliation>
  </overall_official>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <results_first_submitted>August 17, 2011</results_first_submitted>
  <results_first_submitted_qc>August 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2011</results_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticoagulant Treatment</keyword>
  <keyword>Risk Factors For Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study population included male and female participants &gt;18 years of age with chronic non-valvular Atrial Fibrillation. The participants were recruited during the time period from 20 February 2007 to 5 June 2008 at medical clinics in Europe.</recruitment_details>
      <pre_assignment_details>Participants were enrolled in the study up to two weeks before randomisation and treatment assignment. Participants that were already treated with Vitamin K Antagonists (VKA) at the time of enrollment had their dose adjusted to achive INR &lt;2.0 at the time of randomisation. If this was not achieved the participant was discontinued from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>150 mg od</title>
          <description>AZD0837 150 mg od</description>
        </group>
        <group group_id="P2">
          <title>300 mg od</title>
          <description>AZD0837 300 mg od</description>
        </group>
        <group group_id="P3">
          <title>450 mg od</title>
          <description>AZD0837 450 mg od</description>
        </group>
        <group group_id="P4">
          <title>200 mg bd</title>
          <description>AZD0837 200 mg bd</description>
        </group>
        <group group_id="P5">
          <title>VKA INR 2-3</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164">Patients who received treatment</participants>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="160"/>
                <participants group_id="P5" count="318"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>On Treatment Period Started</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="160"/>
                <participants group_id="P5" count="318"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>On Treatment Period Completed</title>
              <participants_list>
                <participants group_id="P1" count="140">Patients who completed treatment</participants>
                <participants group_id="P2" count="129"/>
                <participants group_id="P3" count="128"/>
                <participants group_id="P4" count="128"/>
                <participants group_id="P5" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="129"/>
                <participants group_id="P3" count="128"/>
                <participants group_id="P4" count="128"/>
                <participants group_id="P5" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Development of increasing Liver Function</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fullfillment of exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrolment or randomization</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Interupted IP for more than 7 days</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant not willing to continue</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Criteria from the CSR</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>150 mg od</title>
          <description>AZD0837 150 mg od</description>
        </group>
        <group group_id="B2">
          <title>300 mg od</title>
          <description>AZD0837 300 mg od</description>
        </group>
        <group group_id="B3">
          <title>450 mg od</title>
          <description>AZD0837 450 mg od</description>
        </group>
        <group group_id="B4">
          <title>200 mg bd</title>
          <description>AZD0837 200 mg bd</description>
        </group>
        <group group_id="B5">
          <title>VKA INR 2-3</title>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="156"/>
            <count group_id="B4" value="160"/>
            <count group_id="B5" value="318"/>
            <count group_id="B6" value="949"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" spread="69.9"/>
                    <measurement group_id="B2" value="9.0" spread="69.8"/>
                    <measurement group_id="B3" value="9.4" spread="69.3"/>
                    <measurement group_id="B4" value="9.4" spread="67.8"/>
                    <measurement group_id="B5" value="9.1" spread="68.3"/>
                    <measurement group_id="B6" value="9.18" spread="69.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="103"/>
                    <measurement group_id="B6" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="107"/>
                    <measurement group_id="B5" value="215"/>
                    <measurement group_id="B6" value="650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bleeding Events</title>
        <description>Number of patients with a bleeding event while on study drug. Patients with multiple events are counted once</description>
        <time_frame>36 weeks according to protocol. For patients who discontinued treatment the time frame was &lt;36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Events</title>
          <description>Number of patients with a bleeding event while on study drug. Patients with multiple events are counted once</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="160"/>
                <count group_id="O5" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Creatinine</title>
        <description>Change in Creatinine values from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)</description>
        <time_frame>12 weeks according to protocol.(baseline to week 12 visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Creatinine</title>
          <description>Change in Creatinine values from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="134"/>
                <count group_id="O5" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.95" spread="11.18"/>
                    <measurement group_id="O2" value="4.81" spread="12.74"/>
                    <measurement group_id="O3" value="7.56" spread="14.95"/>
                    <measurement group_id="O4" value="9.22" spread="11.24"/>
                    <measurement group_id="O5" value="0.43" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alanine Aminotransferase (ALAT)</title>
        <description>Number of patients while on study drug with ALAT&gt;=3 times upper limit of normal.l</description>
        <time_frame>36 weeks according to protocol. For patients who discontinued treatment the time frame was &lt;36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALAT)</title>
          <description>Number of patients while on study drug with ALAT&gt;=3 times upper limit of normal.l</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="152"/>
                <count group_id="O5" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bilirubin</title>
        <description>Number of patients while on study drug with Bilirubin&gt;=2 times upper limit of normal</description>
        <time_frame>36 weeks according to protocol. For patients who discontinued treatment the time frame was &lt;36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin</title>
          <description>Number of patients while on study drug with Bilirubin&gt;=2 times upper limit of normal</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="152"/>
                <count group_id="O5" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D-Dimer</title>
        <description>Change in D-Dimer values from enrolment to week 12 visit for VKA naïve patients while on study drug (week 12 visit-enrolment)</description>
        <time_frame>14 weeks according to protocol.(enrolment to week 12 visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>D-Dimer</title>
          <description>Change in D-Dimer values from enrolment to week 12 visit for VKA naïve patients while on study drug (week 12 visit-enrolment)</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.4" lower_limit="-382" upper_limit="170"/>
                    <measurement group_id="O2" value="-76.9" lower_limit="-613" upper_limit="29"/>
                    <measurement group_id="O3" value="-45.2" lower_limit="-1817" upper_limit="230"/>
                    <measurement group_id="O4" value="-68.0" lower_limit="-1313" upper_limit="69"/>
                    <measurement group_id="O5" value="-50.3" lower_limit="-3955" upper_limit="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activated Partial Thromboplastin Time (APTT)</title>
        <description>Change in Activated partial thromboplastin time (APTT) from baseline to week 12 visit for VKA naïve patients while on study drug (week 12 visit-baseline)</description>
        <time_frame>12 weeks according to protocol.(baseline to week 12 visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Activated Partial Thromboplastin Time (APTT)</title>
          <description>Change in Activated partial thromboplastin time (APTT) from baseline to week 12 visit for VKA naïve patients while on study drug (week 12 visit-baseline)</description>
          <units>sec</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="-1" upper_limit="24"/>
                    <measurement group_id="O2" value="12.3" lower_limit="2" upper_limit="110"/>
                    <measurement group_id="O3" value="17.4" lower_limit="-79" upper_limit="52"/>
                    <measurement group_id="O4" value="16.4" lower_limit="2" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ecarin Clotting Time (ECT)</title>
        <description>Change in Ecarin clotting time (ECT) from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)</description>
        <time_frame>12 weeks according to protocol.(baseline to week 12 visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Ecarin Clotting Time (ECT)</title>
          <description>Change in Ecarin clotting time (ECT) from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)</description>
          <units>sec</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="98"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="-1" upper_limit="86"/>
                    <measurement group_id="O2" value="53.0" lower_limit="15" upper_limit="93"/>
                    <measurement group_id="O3" value="64.0" lower_limit="2" upper_limit="134"/>
                    <measurement group_id="O4" value="73.5" lower_limit="-1" upper_limit="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of AZD0837 (Prodrug)</title>
        <description>Assessment made on the week 12 visit</description>
        <time_frame>12 weeks after baseline according to protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of AZD0837 (Prodrug)</title>
          <description>Assessment made on the week 12 visit</description>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.8" lower_limit="10.0" upper_limit="2334.0"/>
                    <measurement group_id="O2" value="617.5" lower_limit="10.0" upper_limit="5355.0"/>
                    <measurement group_id="O3" value="564.5" lower_limit="10.0" upper_limit="14720.0"/>
                    <measurement group_id="O4" value="1143.5" lower_limit="10.0" upper_limit="9644.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of AR-H067637XX (Active Metabolite)</title>
        <description>Assessment made on the week 12 visit</description>
        <time_frame>12 weeks after baseline according to protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of AR-H067637XX (Active Metabolite)</title>
          <description>Assessment made on the week 12 visit</description>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="112"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.8" lower_limit="10.0" upper_limit="503.9"/>
                    <measurement group_id="O2" value="373.6" lower_limit="10.0" upper_limit="1074.0"/>
                    <measurement group_id="O3" value="454.8" lower_limit="10.0" upper_limit="1490.0"/>
                    <measurement group_id="O4" value="600.8" lower_limit="10.0" upper_limit="1523.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TT</title>
        <description>Oral clearance of AR-H067637XX in subgroup of patients with genotype TT for gene polymorphism ABCB1 C3435T</description>
        <time_frame>36 weeks according to protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TT</title>
          <description>Oral clearance of AR-H067637XX in subgroup of patients with genotype TT for gene polymorphism ABCB1 C3435T</description>
          <units>L/h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" lower_limit="22.9" upper_limit="79.7"/>
                    <measurement group_id="O2" value="42.4" lower_limit="13.7" upper_limit="699"/>
                    <measurement group_id="O3" value="36.3" lower_limit="21.4" upper_limit="62.9"/>
                    <measurement group_id="O4" value="35.6" lower_limit="19.7" upper_limit="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TC</title>
        <description>Oral clearance of AR-H067637XX in subgroup of patients with genotype TC for gene polymorphism ABCB1 C3435T</description>
        <time_frame>36 weeks according to protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TC</title>
          <description>Oral clearance of AR-H067637XX in subgroup of patients with genotype TC for gene polymorphism ABCB1 C3435T</description>
          <units>L/h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" lower_limit="19.6" upper_limit="130.5"/>
                    <measurement group_id="O2" value="39.3" lower_limit="17.2" upper_limit="138.6"/>
                    <measurement group_id="O3" value="37.7" lower_limit="18" upper_limit="79.4"/>
                    <measurement group_id="O4" value="40" lower_limit="17.4" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype CC</title>
        <description>Oral clearance of AR-H067637XX in subgroup of patients with genotype CC for gene polymorphism ABCB1 C3435T</description>
        <time_frame>36 weeks according to protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mg od</title>
            <description>AZD0837 150 mg od</description>
          </group>
          <group group_id="O2">
            <title>300 mg od</title>
            <description>AZD0837 300 mg od</description>
          </group>
          <group group_id="O3">
            <title>450 mg od</title>
            <description>AZD0837 450 mg od</description>
          </group>
          <group group_id="O4">
            <title>200 mg bd</title>
            <description>AZD0837 200 mg bd</description>
          </group>
          <group group_id="O5">
            <title>VKA INR 2-3</title>
          </group>
        </group_list>
        <measure>
          <title>Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype CC</title>
          <description>Oral clearance of AR-H067637XX in subgroup of patients with genotype CC for gene polymorphism ABCB1 C3435T</description>
          <units>L/h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="23.7" upper_limit="66"/>
                    <measurement group_id="O2" value="41.1" lower_limit="21.8" upper_limit="62.1"/>
                    <measurement group_id="O3" value="43.4" lower_limit="22.8" upper_limit="78"/>
                    <measurement group_id="O4" value="39.6" lower_limit="26.5" upper_limit="107.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD0837 150 mg od</title>
        </group>
        <group group_id="E2">
          <title>AZD0837 300 mg od</title>
        </group>
        <group group_id="E3">
          <title>AZD0837 450 mg od</title>
        </group>
        <group group_id="E4">
          <title>AZD0837 200 mg bd</title>
        </group>
        <group group_id="E5">
          <title>VKA INR 2-3</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Anal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Periodontal Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Chronic Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal Graft Rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Infective Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Colon Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Prostatic Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Vascular Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Stenosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Axillary Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Peripheral Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>Subclavian Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="67" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="319"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="319"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

